MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 574924 | Name: Trovirdine
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Trovirdine inhibits HIV-1 RT when employing heteropolymeric primer/template (oligo-DNA/ribosomal RNA) and dGTP as substrate.

Chemical Structure

Trovirdine
Trovirdine
CAS#149488-17-5

Theoretical Analysis

MedKoo Cat#: 574924

Name: Trovirdine

CAS#: 149488-17-5

Chemical Formula: C13H13BrN4S

Exact Mass: 336.0044

Molecular Weight: 337.24

Elemental Analysis: C, 46.30; H, 3.89; Br, 23.69; N, 16.61; S, 9.51

Price and Availability

Size Price Availability Quantity
5mg USD 250.00 2 Weeks
10mg USD 410.00 2 Weeks
25mg USD 700.00 2 Weeks
50mg USD 1,100.00 2 Weeks
100mg USD 1,600.00 2 Weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
148311-89-1 (HCl)
Synonym
Trovirdine; LY300046
IUPAC/Chemical Name
1-(5-bromopyridin-2-yl)-3-(2-(pyridin-2-yl)ethyl)thiourea
InChi Key
HOCFDYZWQYGULA-UHFFFAOYSA-N
InChi Code
InChI=1S/C13H13BrN4S/c14-10-4-5-12(17-9-10)18-13(19)16-8-6-11-3-1-2-7-15-11/h1-5,7,9H,6,8H2,(H2,16,17,18,19)
SMILES Code
S=C(NCCC1=NC=CC=C1)NC2=NC=C(Br)C=C2
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 337.24 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Wang JL, Elsheikha HM, Li TT, He JJ, Bai MJ, Liang QL, Zhu XQ, Cong W. Efficacy of antiretroviral compounds against Toxoplasma gondii in vitro. Int J Antimicrob Agents. 2019 Dec;54(6):814-819. doi: 10.1016/j.ijantimicag.2019.08.023. Epub 2019 Aug 31. PMID: 31479744. 2: El-Essawy A, El-Sayed WA, El-Kafrawy SA, Morshedy AS, Abdel-Rahman AH. Anti- hepatitis B virus activity of new 1,2,4-triazol-2-yl- and 1,3,4-oxadiazol-2-yl-2-pyridinone derivatives. Z Naturforsch C J Biosci. 2008 Sep-Oct;63(9-10):667-74. doi: 10.1515/znc-2008-9-1010. PMID: 19040105. 3: Mehanna AS, Belani JD, Kelley CJ, Pallansc LA. Design, synthesis and biological evaluation of a series of thioamides as non-nucleoside reverse transcriptase inhibitors. Med Chem. 2007 Nov;3(6):513-9. doi: 10.2174/157340607782360344. PMID: 18045200. 4: Ladurée D, Sugeac E, Fossey C, Schmidt S, Laumond G, Aubertin AM. Synthesis of certain heterodimers expected as HIV-1 reverse transcriptase inhibitors. Nucleosides Nucleotides Nucleic Acids. 2003 May-Aug;22(5-8):873-5. doi: 10.1081/NCN-120022675. PMID: 14565300. 5: Sugeac E, Fossey C, Ladurée D, Schmidt S, Laumond G, Aubertin AM. Synthesis and anti-HIV activity of some heterodimers [NRTI]-glycyl-succinyl-[trovirdine analogue] of known HIV-1 reverse transcriptase inhibitors. J Enzyme Inhib Med Chem. 2003 Apr;18(2):175-86. doi: 10.1080/1475636032000069846. PMID: 12943202. 6: Gavriliu D, Fossey C, Ciurea A, Delbederi Z, Sugeac E, Ladurée D, Schmidt S, Laumond G, Aubertin AM. Synthesis and anti-HIV activity of [d4U]-[trovirdine analogue] and [d4T]-[trovirdine analogue] heterodimers as inhibitors of HIV-1 reverse transcriptase. Nucleosides Nucleotides Nucleic Acids. 2002;21(8-9):505-33. doi: 10.1081/NCN-120015066. PMID: 12484448. 7: Venkatachalam TK, Sudbeck EA, Mao C, Uckun FM. Stereochemistry of halopyridyl and thiazolyl thiourea compounds is a major determinant of their potency as nonnucleoside inhibitors of HIV-1 reverse transcriptase. Bioorg Med Chem Lett. 2000 Sep 18;10(18):2071-4. doi: 10.1016/s0960-894x(00)00398-x. PMID: 10999473. 8: Uckun FM, Mao C, Pendergrass S, Maher D, Zhu D, Tuel-Ahlgren L, Venkatachalam TK. N-[2-(4-methylphenyl)ethyl]-N'-[2-(5-bromopyridyl)]-thiourea as a potent inhibitor of NNRTI-resistant and multidrug-resistant human immunodeficiency virus type 1. Antivir Chem Chemother. 2000 Mar;11(2):135-40. doi: 10.1177/095632020001100205. PMID: 10819437. 9: Uckun FM, Pendergrass S, Maher D, Zhu D, Tuel-Ahlgren L, Mao C, Venkatachalam TK. N'-[2-(2-thiophene)ethyl]-N'-[2-(5-bromopyridyl)] thiourea as a potent inhibitor of NNI-resistant and multidrug-resistant human immunodeficiency virus-1. Bioorg Med Chem Lett. 1999 Dec 20;9(24):3411-6. doi: 10.1016/s0960-894x(99)00624-1. PMID: 10617082. 10: Mao C, Sudbeck EA, Venkatachalam TK, Uckun FM. Structure-based design of non-nucleoside reverse transcriptase inhibitors of drug-resistant human immunodeficiency virus. Antivir Chem Chemother. 1999 Sep;10(5):233-40. doi: 10.1177/095632029901000502. PMID: 10574178. 11: Uckun FM, Mao C, Pendergrass S, Maher D, Zhu D, Tuel-Ahlgren L, Venkatachalam TK. N-[2-(1-cyclohexenyl)ethyl]-N'-[2-(5-bromopyridyl)]-thiourea and N'-[2-(1-cyclohexenyl)ethyl]-N'-[2-(5-chloropyridyl)]-thiourea as potent inhibitors of multidrug-resistant human immunodeficiency virus-1. Bioorg Med Chem Lett. 1999 Sep 20;9(18):2721-6. doi: 10.1016/s0960-894x(99)00460-6. PMID: 10509923. 12: Mao C, Sudbeck EA, Venkatachalam TK, Uckun FM. Rational design of N-[2-(2,5-dimethoxyphenylethyl)]-N'-[2-(5-bromopyridyl)]-thiourea (HI-236) as a potent non-nucleoside inhibitor of drug-resistant human immunodeficiency virus. Bioorg Med Chem Lett. 1999 Jun 7;9(11):1593-8. doi: 10.1016/s0960-894x(99)00235-8. PMID: 10386942. 13: D'Cruz OJ, Uckun FM. Novel derivatives of phenethyl-5-bromopyridylthiourea and dihydroalkoxybenzyloxopyrimidine are dual-function spermicides with potent anti-human immunodeficiency virus activity. Biol Reprod. 1999 Jun;60(6):1419-28. doi: 10.1095/biolreprod60.6.1419. PMID: 10330101. 14: De Clercq E. Perspectives of non-nucleoside reverse transcriptase inhibitors (NNRTIs) in the therapy of HIV-1 infection. Farmaco. 1999 Jan-Feb;54(1-2):26-45. doi: 10.1016/s0014-827x(98)00103-7. PMID: 10321027. 15: Mao C, Vig R, Venkatachalam TK, Sudbeck EA, Uckun FM. Structure-based design of N-[2-(1-piperidinylethyl)]-N'-[2-(5-bromopyridyl)]-thiourea and N-[2-(1-piperazinylethyl)]-N'-[2-(5-bromopyridyl)]-thiourea as potent non- nucleoside inhibitors of HIV-1 reverse transcriptase. Bioorg Med Chem Lett. 1998 Aug 18;8(16):2213-8. doi: 10.1016/s0960-894x(98)00384-9. PMID: 9873515. 16: Vig R, Mao C, Venkatachalam TK, Tuel-Ahlgren L, Sudbeck EA, Uckun FM. Rational design and synthesis of phenethyl-5-bromopyridyl thiourea derivatives as potent non-nucleoside inhibitors of HIV reserve transcriptase. Bioorg Med Chem. 1998 Oct;6(10):1789-97. doi: 10.1016/s0968-0896(98)00108-4. PMID: 9839009. 17: Cantrell AS, Engelhardt P, Högberg M, Jaskunas SR, Johansson NG, Jordan CL, Kangasmetsä J, Kinnick MD, Lind P, Morin JM Jr, Muesing MA, Noreén R, Oberg B, Pranc P, Sahlberg C, Ternansky RJ, Vasileff RT, Vrang L, West SJ, Zhang H. Phenethylthiazolylthiourea (PETT) compounds as a new class of HIV-1 reverse transcriptase inhibitors. 2. Synthesis and further structure-activity relationship studies of PETT analogs. J Med Chem. 1996 Oct 11;39(21):4261-74. doi: 10.1021/jm950639r. PMID: 8863804. 18: Zhang H, Vrang L, Bäckbro K, Lind P, Sahlberg C, Unge T, Oberg B. Inhibition of human immunodeficiency virus type 1 wild-type and mutant reverse transcriptases by the phenyl ethyl thiazolyl thiourea derivatives trovirdine and MSC-127. Antiviral Res. 1995 Dec;28(4):331-42. doi: 10.1016/0166-3542(95)00056-9. PMID: 8669892. 19: Uberla K, Stahl-Hennig C, Böttiger D, Mätz-Rensing K, Kaup FJ, Li J, Haseltine WA, Fleckenstein B, Hunsmann G, Oberg B, et al. Animal model for the therapy of acquired immunodeficiency syndrome with reverse transcriptase inhibitors. Proc Natl Acad Sci U S A. 1995 Aug 29;92(18):8210-4. doi: 10.1073/pnas.92.18.8210. PMID: 7545297; PMCID: PMC41126. 20: Ahgren C, Backro K, Bell FW, Cantrell AS, Clemens M, Colacino JM, Deeter JB, Engelhardt JA, Hogberg M, Jaskunas SR, et al. The PETT series, a new class of potent nonnucleoside inhibitors of human immunodeficiency virus type 1 reverse transcriptase. Antimicrob Agents Chemother. 1995 Jun;39(6):1329-35. doi: 10.1128/AAC.39.6.1329. PMID: 7574525; PMCID: PMC162736.